NASDAQ:VKTX - Viking Therapeutics Stock Price, Forecast & News

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Viking Therapeutics Inc (NASDAQ:VKTX) issued its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.05. View Viking Therapeutics' Earnings History.

Viking Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Viking Therapeutics.

11 brokers have issued 12 month price objectives for Viking Therapeutics' stock. Their forecasts range from $8.86 to $40.00. On average, they anticipate Viking Therapeutics' share price to reach $18.76 in the next year. This suggests a possible upside of 184.7% from the stock's current price. View Analyst Price Targets for Viking Therapeutics.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viking Therapeutics.

News headlines about VKTX stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Viking Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Viking Therapeutics.

Viking Therapeutics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 14,900,000 shares, a decrease of 5.8% from the December 15th total of 15,810,000 shares. Based on an average daily volume of 1,300,000 shares, the days-to-cover ratio is currently 11.5 days. Approximately 23.1% of the company's stock are sold short. View Viking Therapeutics' Current Options Chain.

Some companies that are related to Viking Therapeutics include Principia Biopharma (PRNB), Xencor (XNCR), Pacira Biosciences (PCRX), Zymeworks (ZYME), Akcea Therapeutics (AKCA), Insmed (INSM), Forty Seven (FTSV), Arvinas (ARVN), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Ligand Pharmaceuticals (LGND), Amneal Pharmaceuticals (AMRX), Corcept Therapeutics (CORT), Endo International (ENDP) and Constellation Pharmaceuticals (CNST).

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Amarin (AMRN), Sorrento Therapeutics (SRNE), Micron Technology (MU), Novavax (NVAX), Energy Transfer LP Unit (ET), AT&T (T) and Advanced Micro Devices (AMD).

(VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

Viking Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Woodstock Corp (0.10%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Ligand Pharmaceuticals Inc and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics.

VKTX stock was bought by a variety of institutional investors in the last quarter, including Woodstock Corp. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton and Lawson Macartney. View Insider Buying and Selling for Viking Therapeutics.

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VKTX stock can currently be purchased for approximately $6.59.

Viking Therapeutics has a market capitalization of $476.22 million. The biotechnology company earns $-22,060,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Viking Therapeutics employs 15 workers across the globe.View Additional Information About Viking Therapeutics.

The official website for Viking Therapeutics is http://www.vikingtherapeutics.com/.

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]